DOP01: Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paperECCO'24Year: 2024
Authors: Rosini, F.(1);Feakins, R.M.(2)*;Borralho Nunes, P.(3);Driessen, A.(4);Gordon, I.O.(5);Zidar, N.(6);Baldin, P.(7);Christensen, B.(8);Danese, S.(9);Herlihy, N.(10);Iacucci, M.(11);Loughrey, M.B.(12);Magro, F.(13);Mookhoek, A.(14);Svrcek, M.(15);
(1)IRCCS- Azienda Ospedaliero-Universitaria di Bologna, Cellular Pathology, Bologna, Italy;(2)Royal Free London NHS Foundation Trust, Department of Cellular Pathology, London, United Kingdom;(3)Hospital Cuf Descobertas, Department of Pathology, Lisbon, Portugal;(4)University Hospital Antwerp, Department of Pathology, Antwerp, Belgium;(5)Robert J. Tomsich Pathology and Laboratory Medicine Institute, Department of Pathology, Cleveland, United States;(6)Institute of Pathology, Department of Cellular Pathology, Ljubljana, Slovenia;(7)Cliniques Universitaires St-Luc, Department of Pathology, Brussels, Belgium;(8)The Royal Melbourne Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(9)IRCCS Ospedale and University Vita-Salute San Raffaele, - Department of Gastroenterology, Milan, Italy;(10)University College London Hospital NHS, Department of Cellular Pathology, London, United Kingdom;(11)APC Microbiome Ireland, College of Medicine and Health, Cork, Ireland;(12)Royal Victoria Hospital, Department of Cellular Pathology, Belfast, United Kingdom;(13)CINTESIS@RISE, Faculty Of Medicine Of The University Of Porto, Porto, Portugal;(14)Institute of Tissue Medicine and Pathology, Department of Cellular Pathology, Bern, Switzerland;(15)AP-HP- Hôpital Saint-Antoine, Department of Pathology, Paris, France;
DOP02: Developing explicit thresholds for outcomes to inform (GRADE) Evidence to Decision frameworks for Inflammatory Bowel Disease guidelines.ECCO'24Year: 2024
Authors: Shaban, N.(1)*;Sinopoulou, V.(2);Vuyyuru, S.(1);Moran, G.(3);Gordon, M.(2);
(1)Nottingham University Hospitals NHS Trust, Gastroenterology, Nottingham, United Kingdom;(2)University of Central Lancashire, School of Medicine and Dentistry, Preston, United Kingdom;(3)NIHR Nottingham Biomedical Research Centre- Nottingham University Hospitals NHS Trust, School of Medicine, Nottingham, United Kingdom;
DOP03: Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey on processes and outcomesECCO'24Year: 2024
Authors: Walsh, A.(1);Fidalgo, C.(2);Adamina, M.(3);Barreiro de Acosta, M.(4);Burisch, J.(5);Drobne, D.(6);Faiz, O.(7);Ferrante, M.(8);Godny, L.(9);Iacucci, M.(10);Jäghult, S.(11);Restellini, S.(12);Rosini, F.(13);Shouval, D.(14);Yanai, H.(15);Fiorino, G.(16,17)*;
(1)John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom;(2)Hospital Beatriz Ângelo, Department of Gastroenterology-, Lisbon, Portugal;(3)Kantonsspital Winterthur, Department of Visceral and Thoracic Surgery, Winterthur, Switzerland;(4)University Hospital Santiago De Compostela, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain;(5)Copenhagen University Hospital – Amager and Hvidovre, Gastrounit- Medical Division, Hvidovre, Denmark;(6)University Medical Centre Ljubiljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia;(7)St. Mark@E@s Hospital, Department of Colorectal Surgery, Harrow, United Kingdom;(8)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(9)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(10)University College of Cork, University of Cork, Cork, Ireland;(11)Karolinska Institutet, Södersjukhuset, Stockholm, Sweden;(12)La Tour Hospital and University of Geneva, Gastroenterology, Geneva, Switzerland;(13)IRCCS Azienda Ospedaliero-Universitaria di Bologna, Cellular Pathology, Bologna, Italy;(14)Schneider Children@E@s Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petah Tikva, Israel;(15)Rabin Medical Center, IBD center- Division of Gastroenterology, Petah Tikva, Israel;(16)San Raffaele Hospital and Vita e Salute San Raffaele University, Gastroenterology and Digestive Endoscopy, Milan, Italy;(17)Azienda Ospedaliera San Camillo-Forlanini, IBD Unit- Department of Gastroenterology and Digestive Endoscopy, Rome, Italy;
DOP04: Screening and management of fistula cancers in patients with perianal fistulising Crohn’s Disease: an expert consensusECCO'24Year: 2024
Authors: Wong, S.Y.(1)*;Rowan, C.(2);Law, C.C.(3);Brockmans, E.D.(4);Khaitov, S.(5);Sachar, D.(6);Altinmakas, E.(7);Ballard, D.(8);Behrenbruch, C.(9);Bislenghi, G.(10);Bonifacio, C.(11);Carvello, M.(12);Cohen, B.(13);Deepak, P.(14);Dige, A.(15);Geldof, J.(16);Hanna, L.(17);Harmath, C.(18);Holubar, S.(19);Lundby, L.(20);Lightner, A.(21);Lung, P.(22);McDonald, B.(23);McGovern, D.(24);Rubin, D.(23);Sebastian, S.(25);Spinelli, A.(26);Verstockt, B.(27);Winata, L.S.H.(28);Tozer, P.(29);Hart, A.(30);Colombel, J.F.(6);
(1)Mount Sinai Hospital, Internal Medicine/Division of Gastroenterology, New York, United States;(2)Beaumont Hospital, Gastroenterology, Dublin, Ireland;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)Universidad Iberoamericana, Medicine, Santo Domingo, Dominican Republic;(5)Ichan School of Medicine at Mount Sinai, Surgery, New York, United States;(6)Ichan School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(7)Ichan School of Medicine at Mount Sinai, Department of Diagnostic- Molecular and Interventional Radiology, New York, United States;(8)Washington University School of Medicine in St. Louis, Radiology, St. Louis, United States;(9)Epworth General Surgery Clinical Institute, Sugery, Melbourne, Australia;(10)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;(11)Humanitas Research Hospital, Radiology, Milan, Italy;(12)Humanitas Research Hospital, Surgery, Milan, Italy;(13)Cleveland Clinic, Gastroenterology, Cleveland, United States;(14)Washington University in St. Louis School of Medicine, Gastroenterology, St. Louis, United States;(15)Aarhus University Hospital, Gastroenterology, Aarhus, Denmark;(16)Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent, Belgium;(17)St. Mark@E@s Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(18)University of Chicago, Radiology, Chicago, United States;(19)Cleveland Clinic, Surgery, Cleveland, United States;(20)Aarhus University Hospital, Surgery, Aarhus, Denmark;(21)Scripps Clinic, Surgery, La Jolla, United States;(22)St. Mark@E@s Hospital, Radiology, London, United Kingdom;(23)University of Chicago, Gastroenterology, Chicago, United States;(24)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles, United States;(25)Hull University Teaching Hospitals, Gastroenterology, Hull, United Kingdom;(26)Humanitas University, Colorectal Surgery, Milan, Italy;(27)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(28)St. Vincent Hospital, Dept of Medical Imaging, Melbourne, Australia;(29)St. Mark@E@s Hospital, Surgery, London, United Kingdom;(30)St. Mark@E@s Hospital, Gastroenterology, London, United Kingdom;TOpCLASS Consortium
DOP05: Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease.ECCO'24Year: 2024
Authors: Revés, J.(1)*;Roager Madsen, G.(2);Burisch, J.(2);Wong, C.(3);Arebi, N.(3);Bonnet-Dodel, M.(4);Buisson, A.(4);Gatt, K.(5);Ellul, P.(5);Vieujean, S.(6);Ordas, I.(7);Duricova, D.(8);Rodríguez-Lago, I.(9);Sebastian, S.(10);Mocanu, I.(11);Kaimakliotis, I.(12);Goldis, A.(13);Hernandez, V.(14,15);Nachury, M.(16);Fumery, M.(17);Alloca, M.(18);Pedersen, N.(19);Barberio, B.(20);Guedes, A.(21);Ribeiro, R.(21);Ungaro, R.(22);Mary, J.Y.(23);Bigot, N.(23);Lambert, J.(23);Colombel, J.F.(22);Torres, J.(1,24);
(1)Hospital Beatriz Ângelo, Department of Gastroenterology, Loures, Portugal;(2)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit medical division, Copenhagen, Denmark;(3)St Mark@E@s National Hospital, Department of IBD, London, United Kingdom;(4)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(5)Mater Dei Hospital, Division of Gastroenterology, Msida, Malta;(6)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(7)Hospital Clinic Barcelona IDIBAPS- CIBER-EHD, IBD Unit- Department of Gastroenterology-, Barcelona, Spain;(8)ISCARE a.s., IBD Clinic and Research Centre, Prague, Czech Republic;(9)Hospital Universitario de Galdakao, Department of Gastroenterology, Galdakao, Spain;(10)Hull University Teaching Hospitals, IBD Research Unit- Department of Gastroenterology, Hull, United Kingdom;(11)Hospital Garcia D@E@Orta, Department of Gastroenterology, Almada, Portugal;(12)American Gastroenterology Center, Department of Gastroenterology and Hepatology, Nicosia, Cyprus;(13)Algomed Policlinic, Department of Gastroenterology, Timisoara, Romania;(14)Hospital Alvaro Cunqueiro, Department of Gastroenterology, Vigo, Spain;(15)Instituto de Investigacion Sanitaria Galicia Sur, Instituto de Investigacion Sanitaria Galicia Sur, Vigo, Spain;(16)Univ. Lille- Inserm- CHU Lille- U1286, INFINITE - Institute for Translational Research in Inflammation- F-59000, Lille, France;(17)CHU Amiens-Picardie, Department of Gastroenterology, Amiens, France;(18)IRCCS OSPEDALE San Raffaele, Gastroenterology and Endoscopy- IBD Center, Milan, Italy;(19)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(20)University of Padua, Division of Gastroenterology- Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(21)Hospital da Luz Learning Health, Investigation Center, Lisbon, Portugal;(22)Mount Sinai Hospital, Department of Gastroenterology, New York, United States;(23)Centre of Research in Epidemiology and Statistics- UMR 1153- Inserm, ECSTRRA Unit, Paris, France;(24)Hospital da Luz, Division of Gastroenterology, Lisboa, Portugal;CROCO Study Group
DOP06: Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumabECCO'24Year: 2024
Authors: Chaemsupaphan, T.(1,2)*;Pudipeddi, A.(1);Paramsothy, S.(1);Kermeen, M.(1);Collins, G.(1);Lin, H.(1,3);Leong, R.W.(1);
(1)Concord Repatriation General Hospital, Gastroenterology, Sydney, Australia;(2)Siriraj Hospital Mahidol University, Gastroenterology, Bangkok, Thailand;(3)Tan tock seng hospital, Gastroenterology, Singapore, Singapore;
DOP07: Monitoring disease activity by intestinal ultrasound predicts biologic treatment persistence in patients with Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Fremberg Ilvemark, J.(1)*;Christensen, K.R.(1);Steenholdt, C.(1);Brynskov, J.(1);Attauabi, M.(1);Dahl, E.(1);Bjerrum, J.W.(1);Seidelin, J.B.(1);
(1)Herlev Hospital- University of Copenhagen, Department of gastroenterology and hepatology, Copenhagen, Denmark;
DOP08: A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in Inflammatory Bowel Disease.ECCO'24Year: 2024
Authors: Baldan-Martin, M.(1)*;Azkargorta, M.(2);Aransay, A.M.(3);Gil-Redondo, R.(4);Moreno-Indias, I.(5);Iloro, I.(2);Soleto, I.(1);Orejudo , M.(1);Ramírez, C.(1);Lucendo, A.J.(6);Rodríguez Gutiérrez, C.(7);Gutiérrez, A.(8);Martín Arranz, E.(9);Bujanda, L.(10);Rodríguez-Lago, I.(11);Riestra, S.(12);Iglesias-Flores, E.(13);Bermejo, F.(14);Van Domselaar, M.(15);García, M.J.(16);Fernández Salazar, L.(17);De Prado, Á.(18);Calvet, X.(19);Torrealba, L.(20);Bastón Rey, I.(21);Pallarés, H.(22);Ber, Y.(23);Carnerero, E.L.(24);Casanova, M.J.(1);Millet, Ó.(4);Elortza, F.(2);Mato, J.M.(4);Tinahones, F.J.(5);Chaparro*, M.(1);Gisbert*, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd- Madrid. Spain, Gastroenterology Unit, Madrid Madrid, Spain;(2)CIC bioGUNE- BRTA Basque Research & Technology Alliance- CIBERehd, Proteomics Platform, Derio, Spain;(3)CIC bioGUNE- Basque Research and Technology Alliance BRTA- CIBERehd, Genome Analysis Platform, Derio, Spain;(4)CIC bioGUNE, Precision Medicine and Metabolism Lab, Derio, Spain;(5)Virgen de la Victoria University Hospital- Málaga- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición CIBEROBN- Instituto de Salud Carlos III, Department of Endocrinology and Nutrition, Madrid, Spain;(6)Hospital General de Tomelloso- Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM- CIBERehd, Gastroenterology Unit, Ciudad Real, Spain;(7)Hospital Universitario de Navarra, Gastroenterology Unit, Pamplona, Spain;(8)Hospital General Universitario de Alicante- CIBERehd and Instituto Investigación Sanitaria y Biomédica de Alicante, Gastroenterology Unit, Alicante, Spain;(9)Hospital Universitario La Paz and Instituto de Investigación Sanitaria La Paz IdiPaz- UAM, Gastroenterology Unit, Madrid, Spain;(10)Hospital Universitario Donostia and Instituto Biodonostia. Universidad del País Vasco UPV/EHU, Gastroenterology Unit, Donostia, Spain;(11)Hospital Universitario de Galdakao- Biocruces Bizkaia HRI, Gastroenterology Unit, Vizcaya, Spain;(12)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(13)Hospital Universitario Reina Sofia, Gastroenterology Unit, Córdoba, Spain;(14)Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain;(15)Hospital Universitario de Torrejón, Gastroenterology Unit, Madrid, Spain;(16)Hospital Universitario Marqués de Valdecilla- IDIVAL- Universidad de Cantabria, Gastroenterology and Hepatology Department, Santander, Spain;(17)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(18)Hospital Universitario Rio Hortega, Gastroenterology Unit, Valladolid, Spain;(19)Consorci Corporació Santitària Parc Taulí- CIBERehd. Sabadell, Gastroenterology Unit, Sabadel, Spain;(20)Hospital Universitario Dr. Josep Trueta, Gastroenterology Unit, Girona, Spain;(21)Hospital Clínico Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain;(22)Hospital Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;(23)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(24)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;*Authors share co-senior authorship.
DOP09: Models for predicting Crohn Disease (CD) exacerbation using serum and fecal metabolomicsECCO'24Year: 2024
Authors: Levhar, N.(1)*;Hadar, R.(1);Braun, T.(1);Efroni, G.(1);Naamneh, R.(1);Agranovich, B.(2);Talan Asher, A.(3);Selinger, L.(3);Picard, O.(3);Lahat, A.(3);Eliakim, A.(3);Kopylov, U.(3);Ben-Horin, S.(3);Amir, A.(1);Haberman, Y.(1);
(1)Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel;(2)Technion Institute, The Ruth and Bruce Rappaport- Faculty of Medicine, Haifa, Israel;(3)Sheba Medical Center, Gastroenterology, Ramat Gan, Israel;
DOP10: Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE TrialECCO'24Year: 2024
Authors: Peyrin-Biroulet, L.(1)*;Bossuyt, P.(2);Regueiro, M.(3);Schreiber, S.(4);Gecse, K.(5);Irving, P.(6);D’Haens, G.(5);Cao , Q.(7);Neimark, E.(8);Huang, X.(9);Anschutz, T.(8);Kligys, K.(10);O’Brien, D.(10);Panaccione, R.(11);
(1)University Hospital of Nancy-Brabois, Department of Gastroenterology, Vandoeuvre-les-Nancy, France;(2)Imelda General Hospital, Imelda GI Clinical Research Center- Department of Gastroenterology, Bonheiden, Belgium;(3)Cleveland Clinic, Department of Gastroenterology- Hepatology and Nutrition, Cleveland, United States;(4)Christian-Albrechts-University, Department of Medicine I- University Hospital Schleswig-Holstein, Kiel, Germany;(5)Amsterdam University Medical Center- Location AMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Guy@E@s and St Thomas@E@ NHS Foundation Trust, Gastroenterology- Guy@E@s and St Thomas@E@ Hospital, London, United Kingdom;(7)Zhejiang University, Department of Gastroenterology- Sir Run Run Shaw Hospital- College of Medicine, Hangzhou, China;(8)AbbVie, Clinical Development, North Chicago, United States;(9)AbbVie, Statistics, North Chicago, United States;(10)AbbVie, Medical Affairs, North Chicago, United States;(11)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;
DOP11: Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trialECCO'24Year: 2024
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Adsul, S.(5);Colombel , J.F.(6); D’Haens, G.R.(7);Freire, M.(5);Moran, G.W.(8,9);Peyrin-Biroulet, L.(10,11,12,13,14);Sandborn, W.J.(15);Sebastian, S.(16);Travis, S.(17);Vermeire, S.(18);Hanžel, J.(3,19);Ma, C.(3,20,21);Sedano, R.(1,3);Sheridan, P.(3);Arya , N.(22);Beaton, M.(1);Bossuyt, P.(23);Danese, S.(24);Green, D.(25);Harlan III, W.(26);Horynski , M.(27);Kierkus, J.(28);Kopoń, A.(29);Klopocka, M.(30,31);Petroniene , R.(32);Silverberg, M.S.(33);Wolanski, L.(34);Feagan, B.G.(1,2,3);
(1)University of Western Ontario, Department of Medicine- Division of Gastroenterology, London, Canada;(2)University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada;(3)Alimentiv Inc., Medical R&D, London, Canada;(4)University of Western Ontario, Robarts Research Institute- Schulich School of Medicine and Dentistry, London, Canada;(5)Takeda Pharmaceuticals, Global Medical Affairs, Cambridge, United States;(6)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(7)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)University of Nottingham, Nottingham Digestive Diseases Biomedical Research Centre, Nottingham, United Kingdom;(9)Nottingham University Hospitals NHS Trust, NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom;(10)Nancy University Hospital, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(11)University of Lorraine, Inserm- NGERE, Nancy, France;(12)Nancy University Hospital, INFINY Institute, Vandœuvre-lès-Nancy, France;(13)Nancy University Hospital, FHU CUring and pREventing immune-mediated inflammatory disease FHU-CURE, Vandœuvre-lès-Nancy, France;(14)Groupe Hospitalier Privé Ambroise Paré – Hartmann, Paris IBD Center, Neuilly sur Seine, France;(15)Division of Gastroenterology, University of California San Diego, La Jolla, United States;(16)Hull University Teaching Hospitals, IBD Unit, Hull, United Kingdom;(17)University of Oxford, Kennedy Institute and Biomedical Research Centre, Oxford, United Kingdom;(18)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(19)University of Ljubljana, Department of Gastroenterology- Faculty of Medicine, Ljubljana, Slovenia;(20)University of Calgary, Division of Gastroenterology & Hepatology- Cumming School of Medicine, Calgary, Canada;(21)University of Calgary, Department of Community Health Sciences- Cumming School of Medicine, Calgary, Canada;(22)ABP Research Services Corp., Oakville Endoscopy Centre, Oakville, Canada;(23)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(24)IRCCS San Raffaele Scientific Institute- Vita-Salute San Raffaele University, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(25)Taunton Surgical Centre, Department of Gastroenterology, Oshawa, Canada;(26)Asheville Gastroenterology Associates, Gastroenterology, Asheville, United States;(27)Endoskopia Sp. z.o.o., Gastroenterology, Sopot, Poland;(28)The Children’s Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders- and Pediatrics, Warsaw, Poland;(29)Toruńskie Centrum Gastrologiczne Gastromed, Department of Gastroenterology, Toruń, Poland;(30)Collegium Medicum- Nicolaus Copernicus University, Department of Gastroenterology and Nutritional Disorders, Bydgoszcz, Poland;(31)Dr Jana Biziel University Hospital n 2 in Bydgoszcz, Gastroenterology Clinic, Bydgoszcz, Poland;(32)Barrie GI Associates Inc., Gastroenterology, Barrie, Canada;(33)Toronto Immune and Digestive Health Institute, Gastroenterology, Toronto, Canada;(34)Samodzielny Publiczny Zakład Opieki Zdrowotnej w Łęcznej, Gastroenterological Department, Łęcznej, Poland;
DOP12: Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trialECCO'24Year: 2024
Authors: Vermeire, S.(1)*;Peyrin-Biroulet, L.(2);Danese, S.(3);Dubinsky, M.(4);Dulai, P.(5);Tilg, H.(6);Siegmund, B.(7);Gineste, P.(8);Sloan, S.(8);Rabbat, C.(9);Sands, B.E.(10);
(1)University hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(2)CHU de Nancy Université de Lorraine, Service de Gastroentérologie, Nancy, France;(3)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(4)Icahn School of Medicine Mount Sinai, Marie and Barry Lipman IBD Preconception and Pregnancy Clinic, New York, United States;(5)Feinberg School of Medicine Northwestern University, Gastroenterology and Hepatology, Chicago, United States;(6)Medical University Innsbruck, Department of Internal Medicine- Gastroenterology- Hepatology- & Endocrinology, Innsbruck, Austria;(7)Charité- Universitätsmedizin, Medizinische Klinik m. S. Gastroenterologie- Infektiologie und Rheumatologie-, Berlin, Germany;(8)Abivax, Clinical Operations, Paris, France;(9)Abivax, Medical Affairs, Paris, France;(10)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
DOP13: Effect of 8 weeks of combined aerobic and resistance exercise on quality of life, muscle strength, aerobic capacity, and disease activity in patients with Inflammatory Bowel Disease; a parallel group randomized clinical trialECCO'24Year: 2024
Authors: Mirmoosavi, S.(1);Alborzi Avanaki, F.(1)*;Javaherian, M.(2);Tabatabaei, B.(2);
(1)Imam Khomeini Hospital Complex- Tehran University of Medical Sciences, Department of Gastroenterology and Hepatology, Tehran, Iran- Islamic Republic Of;(2)Liver Transplantation Research Center- Imam Khomeini Hospital Complex-Tehran University of Medical Sciences, Department of Internal Medicine, Tehran, Iran- Islamic Republic Of;
DOP14: Proctocolectomy is associated with improved transplant-free survival in patients with primary sclerosing cholangitis: results from a pooled collaborative international studyECCO'24Year: 2024
Authors: Mol, B.(1)*;van Nieuwamerongen, M.(1);Färkkilä, M.(2);Folseraas, T.(3);Boberg, K.(3);Vesterhus, M.(4);Bergquist, A.(5);Bogaards, H.(6);Ponsioen, C.(1);
(1)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Helsinki University Hospital, Gastroenterology and Hepatology, Helsinki, Finland;(3)Oslo University Hospital, Norwegian PSC Research Centre- Department of Transplantation Medicine, Oslo, Norway;(4)University of Bergen, Medicine- Haraldsplass Deaconess Hospital and Department of Clinical Science, Bergen, Norway;(5)Karolinska University Hospital, Gastroenterology and Rheumatology, Stockholm, Sweden;(6)Amsterdam UMC, Epidemiology and Data Science, Amsterdam, The Netherlands;EpiPSC2
DOP15: Results of a pragmatic multicentred randomised controlled trial investigating the use of personalised golimumab dosing in Ulcerative Colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis)ECCO'24Year: 2024
Authors: Doherty, G.(1)*;Coe, C.(1);Egan, L.(2);Kevans, D.(3);O@E@Toole, A.(4);Cullen , G.(1);Galligan, M.(5);McCarthy, J.(6);Slattery, E.(2);McShane, C.(7);O@E@Connell, J.(7);Mulcahy, H.(1);Leyden, J.(8);Godwin, N.(4);Keogh, A.(9);Patchett, S.(4);Sheridan, J.(1);
(1)St Vincent@E@s University Hospital and University College Dublin, Department of Gastroenterology and School of Medicine, Dublin, Ireland;(2)University Hospital and University of Galway, Department of Gastroenterology and School of Medicine, Galway, Ireland;(3)St James@E@ Hospital and Trinity College Dublin, School of Medicine, Dublin, Ireland;(4)Beaumont Hospital and Royal College of Surgeons in Ireland, Department of Gastroenterology and School of Medicine, Dublin, Ireland;(5)University College Dublin, School of Medicine, Dublin, Ireland;(6)Mercy University Hospital and University College Cork, Department of Gastroenterology and School of Medicine, Dublin, Ireland;(7)St James@E@ Hospital and Trinity College Dublin, Department of Gastroenterology and School of Medicine, Dublin, Ireland;(8)Mater Misericordiae University Hospital and University College Dublin, GI Unit and School of Medicine, Dublin, Ireland;(9)Uniiversity Hospital and University of Galway, Department of Gastroenterology and School of Medicine, Galway, Ireland;INITIATIVE network (www.initiativeibd.ie)
DOP16: Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extensionECCO'24Year: 2024
Authors: Siegel, C.(1)*;Danese, S.(2);Rubin, D.T.(3);Sabino, J.(4);Long, M.D.(5);Cross, R.K.(6);Armuzzi, A.(7,8);Blumenstein, I.(9);Kobayashi, T.(10);Lama, S.(11);Charles, L.(11);Cetin, V.(11);Petersen, A.(11);Wu, H.(11);Wang, D.(12);Jain, A.(11);D@E@Haens, G.(13);
(1)Dartmouth-Hitchcock Clinic, Gastroenterology, Lebanon, United States;(2)Department of Gastroenterology and Endoscopy- IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;(3)University of Chicago Medicine- Inflammatory Bowel Disease Center, Inflammatory Bowel Diseases, Chicago, United States;(4)Department of Gastroenterology- University Hospitals Leuven-, Gastroenterology, Leuven, Belgium;(5)UNC Chapel Hill, Gastroenterology and Hepatology, Chapel Hill, United States;(6)University of Maryland School of Medicine, Gastroenterology and Hepatology, Baltimore, United States;(7)IBD Center- IRCCS Humanitas Research Hospital- Rozzano, Inflammatory Bowel Disease, Milan, Italy;(8)Department of Biomedical Sciences- Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;(9)Goethe University Hospital, Inflammatory Bowel Disease, Frankfurt, Germany;(10)Kitasato University Kitasato Institute Hospital, Gastroenterology, Tokyo, Japan;(11)Bristol Myers Squibb, n/a, Princeton, United States;(12)Bristol Myers Squibb K. K., n/a, Tokyo, Japan;(13)Amsterdam University Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands;
DOP17: Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted ComparisonECCO'24Year: 2024
Authors: Gros, B.(1,2)*;Constantine-Cooke, N.(3,4);Kennedy, J.(5);Elford, A.T.(5,6);O’Hare, C.(5,7);Noble, C.(5);Jones, G.R.(5,8);Arnott, I.D.(5);Plevris, N.(5);Lees, C.W.(4,5);
(1)Western General Hospita, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Reina Sofía University Hospital, Gastroenterology and Hepatology, Cordoba, Spain;(3)Western General Hospital, MRC Human Genetics Unit- Institute of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(4)Western General Hospital, Centre for Genomics and Experimental Medicine- Institute of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(5)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(6)The University of Melbourne, Faculty of Medicine, Melbourne, Australia;(7)Western General Hospital, Edinburgh Pharmacy Unit, Edinburgh, United Kingdom;(8)University of Edinburgh, Centre for Inflammation Research- The Queen@E@s Medical Research Institute-, Edinburgh, United Kingdom;
DOP18: Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trialECCO'24Year: 2024
Authors: Peyrin-Biroulet, L.(1)*;Colombel, J.F.(2);D’Haens, G.(3);Dubinsky, M.(2);Cao, Q.(4);Kligys, K.(5);Garrison, A.(5);Huang, X.(5);Neimark, E.(5);Anschutz, T.(5);Crowley, J.(5);Panaccione, R.(6);
(1)Nancy University Hospital, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(2)Icahn School of Medicine at Mt. Sinai, Department of Gastroenterology, New York, United States;(3)Amsterdam UMC campus AMC, Department of Gastroenterology, Amsterdam, Netherlands Antilles;(4)Inflammatory Bowel Disease Center- Sir Run Run Shaw Hospital- College of Medicine Zhejiang University, Department of Gastroenterology, Hangzhou, China;(5)AbbVie Inc., Research and Development, North Chicago, United States;(6)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;
DOP19: High dimensional profiling of IL-23-responsive cells revealed molecular signatures that predict response to anti-IL-23 therapy in patients with Crohn’s DiseaseECCO'24Year: 2024
Authors: Cao, S.(1)*;Colonna, M.(2);Deepak, P.(3);
(1)Washington University in St. Louis, Gastroenterology, St. Louis, United States;(2)Washington University, Pathology and Immunology, St. Louis, United States;(3)Washington University, Gastroenterology, St. Louis, United States;
DOP20: Changes in systemic antibody epitope repertoires from preclinical to established Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Bourgonje, A.R.(1,2)*;Andreu-Sánchez, S.(3);Gacesa, R.(2);Klompus, S.(4);Kalka, I.N.(4);Leviatan, S.(4);Weinberger, A.(4);Segal, E.(4);Fu, J.(3);Zhernakova, A.(3);Vogl, T.(5);Weersma, R.K.(2);
(1)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(3)University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands;(4)Weizmann Institute of Science, Department of Computer Science and Applied Mathematics and Department of Molecular Cell Biology, Rehovot, Israel;(5)Medical University of Vienna, Center for Cancer Research, Vienna, Austria;Lifelines Cohort Study